Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa.
D001921:Brain / Q000378:metabolism; D002849:Chromatography, Gas; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D005463:Fluoroacetates; D006018:Glycols / Q000134:cerebrospinal fluid*; D006801:Humans; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D013237:Stereoisomerism; D014316:Tritium
D005463:Fluoroacetates; D006018:Glycols; D010648:Phenylacetates; D014316:Tritium; D004295:Dihydroxyphenylalanine; D009638:Norepinephrine